Is Celgene Considering Going Private?
Celgene has a deep pipeline and a $69 billion market cap, but it could consider going private in 2019 via a leveraged buyout. Source: BioSpace
TGA Announces Overhaul of Drug Advertising Regulations
Australia’s Therapeutic Goods Administration will impose heavier sanctions for violations of its regulations on drug advertising, but the agency also will phase out its requirement that certain drug advertisements be…
MHRA Issues New Guidance on GXP Data Integrity Compliance
The U.K.’s Medicines and Healthcare products Regulatory Agency released new guidance on its approach to GXP data integrity and its expectations for achieving compliance. Source: Drug Industry Daily
Court Rules Walgreens Must Face Most Claims in Generics Overcharging Class Action
A federal judge ruled a proposed class action accusing Walgreens of overcharging for generic drugs must go forward. Source: Drug Industry Daily
Bipartisan Bill Would Allow DEA to Factor Overdoses, Public Health Into Opioid Quotas
A bipartisan bill introduced in the Senate would widen the Drug Enforcement Administration’s discretion in setting opioid production quotas, allowing the DEA to factor abuse rates and overdose deaths into…
House Fails to Pass New Version of Right-to-Try Legislation
The House of Representatives failed to pass the latest iteration of federal right-to-try legislation Tuesday night. Source: Drug Industry Daily
Right-To-Try Drug Bill Defeated in House
Federal right-to-try legislation that would have allowed terminally ill patients access to experimental therapies without approval from the U.S. Food and Drug Administration failed to muster enough support in the…
Auris Medical Fails Again in Phase III Trial
Auris Medical has gone down swinging again in attempting to develop a treatment for tinnitus after it announced its Phase III trial failed to meet endpoints. Source: BioSpace
PharmaJet Releases Positive Phase I Results for Hantavirus Vaccines
PharmaJet released positive interim results from the U.S. Army’s Phase I clinical trial of two hantavirus vaccines to prevent hemorrhagic fever with renal syndrome (HFRS). Source: BioSpace
Foghorn Therapeutics Launches with $50 Million
Foghorn Therapeutics has officially launched with a $50 million investment and the ambitious goal of altering the way our genes work. Source: BioSpace
- Go to the previous page
- 1
- …
- 143
- 144
- 145
- 146
- 147
- 148
- 149
- …
- 610
- Go to the next page